- Home
- CXW vs RCUS Comparison
CXW vs RCUS Comparison
Compare CXW & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CXW | RCUS |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.2B |
| IPO Year | 2001 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CXW | RCUS |
|---|---|---|
| Price | $29.97 | $18.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $41.80 | $40.00 |
| AVG Volume (30 Days) | 1.8M | ★ 1.9M |
| Earning Date | 11-04-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.19 | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $2,211,182,000.00 | $247,000,000.00 |
| Revenue This Year | $22.27 | N/A |
| Revenue Next Year | $8.36 | N/A |
| P/E Ratio | $38.72 | ★ N/A |
| Revenue Growth | ★ 12.72 | N/A |
| 52 Week Low | $15.74 | $17.43 |
| 52 Week High | $36.55 | $31.74 |
Technical Indicators
Market Signals| Indicator | CXW | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 41.16 | 28.06 |
| Support Level | $29.97 | N/A |
| Resistance Level | $34.69 | $24.38 |
| Average True Range (ATR) | 1.55 | 1.68 |
| MACD | -0.30 | -0.40 |
| Stochastic Oscillator | 28.48 | 16.87 |
Price Performance
Historical ComparisonAbout CXW CoreCivic Inc.
CoreCivic Inc is an owner and operator of private prisons and detention centers in the United States. It operates in three segments: Safety, Community, and Properties. The Community segment owns and operates residential reentry centers. The Properties segment owns properties for lease to third parties and government agencies. The vast majority of the company's revenue comes from the CoreCivic Safety segment which consists of correctional and detention facilities that are owned, or controlled via a long-term lease, and managed by the company, as well as those correctional and detention facilities owned by third parties but managed by CoreCivic.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.